Management of Metastatic Hepatocellular Carcinoma with Lung Metastasis and Child-Pugh B

First-Line Systemic Therapy Selection

The American Association for the Study of Liver Diseases recommends sorafenib as the first-line systemic therapy for patients with metastatic hepatocellular carcinoma and Child-Pugh B liver function, with evidence limited to B7 scores 1, 2, 3
For patients with Child-Pugh B7 and good performance status, sorafenib 400 mg orally twice daily is considered the standard treatment, according to the 2022 KLCA-NCC Korea guidelines with B1 level evidence 1, 2, 3
The European Association for the Study of the Liver provides B1 level evidence supporting sorafenib use in Child-Pugh B7 patients 1, 3
Atezolizumab plus bevacizumab and durvalumab plus tremelimumab are not recommended for Child-Pugh B patients due to lack of clinical trial data, as stated by the American Gastroenterological Association 1, 4

The American Gastroenterological Association states that atezolizumab plus bevacizumab has no efficacy or safety data for Child-Pugh B or C patients 4
Lenvatinib has limited data on efficacy and adverse events in Child-Pugh B or C, according to the European Association for the Study of the Liver 4
All second-line agents, including regorafenib, cabozantinib, ramucirumab, pembrolizumab, and nivolumab, require Child-Pugh A and are not recommended for Child-Pugh B, as stated by the American Association for the Study of Liver Diseases 1, 5, 6

The European Association for the Study of the Liver recommends monitoring liver function tests every 2-4 weeks during the first 2 months of sorafenib therapy 1
The American Association for the Study of Liver Diseases advises watching for signs of hepatic decompensation, such as worsening ascites, encephalopathy, or rising bilirubin, during sorafenib treatment 1

The American Association for the Study of Liver Diseases states that no second-line agents are approved for Child-Pugh B patients 1, 5, 6
All second-line therapies require Child-Pugh A and good performance status, according to the European Association for the Study of the Liver 5, 6

The American Association for the Study of Liver Diseases recommends external beam radiation therapy for palliating symptoms from lung metastases, with B1 level evidence 1, 7, 8
The European Association for the Study of the Liver suggests that radiotherapy may be particularly useful for symptomatic bone metastases if they develop 7, 8
The American Gastroenterological Association advises careful adjustment of opioid selection and dosing based on liver function in Child-Pugh B patients 1, 3

The American Association for the Study of Liver Diseases warns against using immunotherapy combinations in Child-Pugh B due to lack of safety or efficacy data 1, 4
The European Association for the Study of the Liver cautions against premature discontinuation of treatment, as treatment duration is an independent predictor of survival 5, 6